BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25200032)

  • 1. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome).
    Lyseng-Williamson KA
    BioDrugs; 2014 Oct; 28(5):465-75. PubMed ID: 25200032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
    Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
    Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome).
    Hendriksz CJ
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1521-1532. PubMed ID: 27855521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
    Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
    Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial.
    Hendriksz CJ; Giugliani R; Harmatz P; Mengel E; Guffon N; Valayannopoulos V; Parini R; Hughes D; Pastores GM; Lau HA; Al-Sayed MD; Raiman J; ; Yang K; Mealiffe M; Haller C
    Mol Genet Metab; 2015 Feb; 114(2):178-85. PubMed ID: 25284089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elosulfase alfa.
    Haddley K
    Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elosulfase alfa: first global approval.
    Sanford M; Lo JH
    Drugs; 2014 Apr; 74(6):713-8. PubMed ID: 24700469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study.
    Hendriksz CJ; Burton B; Fleming TR; Harmatz P; Hughes D; Jones SA; Lin SP; Mengel E; Scarpa M; Valayannopoulos V; Giugliani R; ; Slasor P; Lounsbury D; Dummer W
    J Inherit Metab Dis; 2014 Nov; 37(6):979-90. PubMed ID: 24810369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome.
    Hendriksz CJ; Parini R; AlSayed MD; Raiman J; Giugliani R; Solano Villarreal ML; Mitchell JJ; Burton BK; Guelbert N; Stewart F; Hughes DA; Berger KI; Slasor P; Matousek R; Jurecki E; Shaywitz AJ; Harmatz PR
    Mol Genet Metab; 2016 Sep; 119(1-2):131-43. PubMed ID: 27380995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
    Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
    PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.
    Harmatz PR; Mengel E; Geberhiwot T; Muschol N; Hendriksz CJ; Burton BK; Jameson E; Berger KI; Jester A; Treadwell M; Sisic Z; Decker C
    Am J Med Genet A; 2017 Feb; 173(2):375-383. PubMed ID: 27774754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome.
    Qi Y; Musson DG; Schweighardt B; Tompkins T; Jesaitis L; Shaywitz AJ; Yang K; O'Neill CA
    Clin Pharmacokinet; 2014 Dec; 53(12):1137-47. PubMed ID: 25234648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.
    Lee CL; Chuang CK; Chiu HC; Tu RY; Lo YT; Chang YH; Lin SP; Lin HY
    Drug Des Devel Ther; 2022; 16():143-154. PubMed ID: 35046639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.
    Jones SA; Bialer M; Parini R; Martin K; Wang H; Yang K; Shaywitz AJ; Harmatz P
    Pediatr Res; 2015 Dec; 78(6):717-22. PubMed ID: 26331768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.
    Nakamura-Utsunomiya A; Nakamae T; Kagawa R; Karakawa S; Sakata S; Sakura F; Tani C; Matsubara Y; Ishino T; Tajima G; Okada S
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32024277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment.
    Hendriksz C; Santra S; Jones SA; Geberhiwot T; Jesaitis L; Long B; Qi Y; Hawley SM; Decker C
    Mol Genet Metab; 2018 Apr; 123(4):479-487. PubMed ID: 29526614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy].
    Politei J; Schenone AB; Guelbert N; Fainboim A; Szlago M
    Arch Argent Pediatr; 2015 Aug; 113(4):359-64. PubMed ID: 26172013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.
    Peracha H; Sawamoto K; Averill L; Kecskemethy H; Theroux M; Thacker M; Nagao K; Pizarro C; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):18-37. PubMed ID: 29779902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme Replacement Therapies and Immunogenicity in Lysosomal Storage Diseases: Is There a Pattern?
    Harmatz P
    Clin Ther; 2015 Sep; 37(9):2130-4. PubMed ID: 26243075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa.
    Hughes D; Giugliani R; Guffon N; Jones SA; Mengel KE; Parini R; Matousek R; Hawley SM; Quartel A
    Orphanet J Rare Dis; 2017 May; 12(1):98. PubMed ID: 28535791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.